Beez M, Dietl H
Infusionsther Klin Ernahr. 1979;6(1):23-6.
The frequency of anaphylacotid reactions following the infusion of colloidal volume substitutes has become more transparent in the recent years due to retrospective reports of several hospitals and especially by a prospective multi-clinical study carried out in the Bavarian area. As a contribution towards medicament safety by the manufacturers of infusion solutions, a quantitation of the incidents should be tried. For the period January 1974-June 1977 Dr. E. Fresenius KG has compared the units sold of HES (Plasmasteril) and Dextran 75 (Longasteril 75) with the reported incidents. The frequency of severe anaphylactoid reactions (type III + IV) amounted to 19/458 924 = 0.0041% for Dextran 75 and to 2/550 350 = 0.0004% for hydroxyethyl starch. The frequency of life-threatening incidents with HES proved to be lower than for Dextran 75 by the factor 10.
近年来，由于几家医院的回顾性报告，尤其是巴伐利亚地区开展的一项前瞻性多中心研究，输注胶体容量替代物后过敏样反应的发生率变得更加清晰。作为输液溶液制造商对药物安全性的贡献，应该尝试对这些事件进行定量分析。1974年1月至1977年6月期间，E. Fresenius KG博士将羟乙基淀粉（Plasmasteril）和右旋糖酐75（Longasteril 75）的销售单位与报告的事件进行了比较。严重过敏样反应（III + IV型）的发生率，右旋糖酐75为19/458924 = 0.0041%，羟乙基淀粉为2/550350 = 0.0004%。羟乙基淀粉危及生命事件的发生率比右旋糖酐75低10倍。
